XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 
  Home
 
 Latest Research
 Cancer
  Breast
  Skin
  Blood
  Prostate
  Liver
  Colon
  Thyroid
  Endometrial
  Brain
  Therapy
  Risk Factors
  Esophageal
  Bladder
  Lung
   Small Cell Carcinoma
  Rectal Cancer
  Pancreatic Cancer
  Bone Cancer
  Cervical Cancer
  Testicular Cancer
  Gastric Cancer
  Ovarian Cancer
  Nerve Tissue
  Renal Cell Carcinoma
 Psychiatry
 Genetics
 Surgery
 Aging
 Ophthalmology
 Gynaecology
 Neurosciences
 Pharmacology
 Cardiology
 Obstetrics
 Infectious Diseases
 Respiratory Medicine
 Pathology
 Endocrinology
 Immunology
 Nephrology
 Gastroenterology
 Biotechnology
 Radiology
 Dermatology
 Microbiology
 Haematology
 Dental
 ENT
 Environment
 Embryology
 Orthopedics
 Metabolism
 Anaethesia
 Paediatrics
 Public Health
 Urology
 Musculoskeletal
 Clinical Trials
 Physiology
 Biochemistry
 Cytology
 Traumatology
 Rheumatology
 
 Medical News
 Health
 Opinion
 Healthcare
 Professionals
 Launch
 Awards & Prizes
 
 Careers
 Medical
 Nursing
 Dental
 
 Special Topics
 Euthanasia
 Ethics
 Evolution
 Odd Medical News
 Feature
 
 World News
 Tsunami
 Epidemics
 Climate
 Business
Search

Last Updated: Nov 17th, 2006 - 22:35:04

Lung Channel
subscribe to Lung newsletter

Latest Research : Cancer : Lung

   DISCUSS   |   EMAIL   |   PRINT
Aerosolized Cyclosporine Shows Significant Results in Chronic Rejection of Allogenic Lung Transplants
Mar 24, 2005, 09:22, Reviewed by: Dr.

The aerosolized cyclosporine NDA (50-799) includes a single pivotal trial that showed significant results in chronic rejection of allogenic lung transplants, but not in acute rejection.

 
The Pulmonary-Allergy Drugs Advisory Committee will review Chiron’s aerosolized cyclosporine Pulminiq for lung transplantation June 6.

The committee discussion likely will focus on additional analyses of pivotal data.

Chiron confirmed that FDA extended aerosolized cyclosporine’s priority review deadline of April 15 by 90 days following the firm’s submission of additional analyses earlier this year.

The company had been expecting the 90-day extension following FDA’s request for further analysis of the NDA’s pivotal trial.

The aerosolized cyclosporine NDA (50-799) includes a single pivotal trial that showed significant results in chronic rejection of allogenic lung transplants, but not in acute rejection.

Chiron is seeking approval for use of aerosolized cyclosporine in combination with standard immunosuppressive therapy to increase survival and prevent chronic rejection in patients receiving allogenic lung transplants.

This would be the first immunosuppresant approved for the indication, Chiron said.
 

- FDA Advisory Committee
 

FDA Advisory Committee

 
Subscribe to Lung Newsletter
E-mail Address:

 

This meeting will be held June 6, 2005 at the CDER advisory committee conference room in Rockville, Md. beginning at 8 a.m.

Related Lung News

Gene Expression Profiling Not Quite Perfected in Predicting Lung Cancer Prognosis
I-ELCAP study: Lung cancer can be detected early with annual low-dose CT screening
Key to lung cancer chemotherapy resistance revealed
3D-CRT brings hope for inoperable lung cancers
Sunitinib Malate shows promise against advanced form of lung cancer
Tarceva-Celebrex Combination therapy shows promising results in advanced lung cancer
Lung cancer susceptibility runs in families - Study
Do Variants in the GST Detoxification Genes Affect the Risk of Lung Cancer?
Tumor diameter - an important prognostic indicator for curability
Palliative radiation can cure some NSCLC


For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 

© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us